GL1X · GenesisL1 explorer

MolNFT v1 · #164524 · protein

Crystal structure of CYP124 in complex with inhibitor carbethoxyhexyl imidazole

6T0K: “Crystal structure of CYP124 in complex with inhibitor carbethoxyhexyl imidazole”. X-ray diffraction, 4 ligands (HEM, M65, MG), 5 pockets (best druggability 0.89). MolNFT v1 #164524 on GenesisL1: 3D structure, binding sites and…

PDB
6T0K
Type
protein
Length
430 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
CYP124 in complex with inhibitor carbethoxyhexyl imidazole
UniProt
P9WPP3
Ligands
HEM, M65, MG, CL
Pockets
5 · best druggability 0.89

Structure

x-ray diffraction · 1 distinct chain · 49% helix, 11% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACYP124 in complex with inhibitor carbethoxyhexyl imidazoleprotein43049% helix, 11% strandP9WPP3

Ligands and binding sites

  • HEM · Protoporphyrin IX containing Fe · ligand · chains A
  • M65 · ethyl 7-imidazol-1-ylheptanoate · ligand · chains A
  • MG · Magnesium ion · metal · 2 copies · chains A
  • CL · Chloride ion · ion · chains A
  • GOL · Glycerol · additive · 4 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16370.890.9473HEM, M65, GOL
21730.710.8933GOL, CL
3610.480.8417empty
4620.300.7517empty
5600.300.7513empty

Compared structures

  • 6T0K · Crystal structure of CYP124 in complex with inhibitor carbethoxyhexyl imidazole · the same entry in another collection · chain A against A, TM-score 1.00
  • P9WPP3 · AlphaFold monomer V2.0 prediction for methyl-branched lipid omega- hydroxylase (P9WPP3) · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.